Patents by Inventor Jonathan Michael Gerber

Jonathan Michael Gerber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for identifying leukemia stem cells and distinguishing them from normal hematopietic stem cells in patients with acute myeloid leukemia: uses in diagnosis, treatment, and research
    Patent number: 9012215
    Abstract: Using the methods of the present invention, intermediate (int) levels of aldehyde dehydrogenase (ALDH) activity reliably distinguished leukemic CD34+CD38? cells capable of engrafting immunodeficient mice, from residual normal hematopoietic stem cells that exhibited relatively higher ALDH activity. Minimal residual disease (MRD) detected during complete remission was enriched for the CD34+CD38?ALDHint leukemic cells, and the presence of these cells after therapy highly correlated with subsequent clinical relapse. The methods of the present invention can distinguish normal from leukemic CD34+CD38? cells, and identifies those AML cells associated with relapse. Methods of prediction of relapse of AML patients and methods of treatment are also provided.
    Type: Grant
    Filed: September 24, 2012
    Date of Patent: April 21, 2015
    Assignee: The Johns Hopkins University
    Inventors: Jonathan Michael Gerber, Richard John Jones
  • METHODS FOR IDENTIFYING LEUKEMIA STEM CELLS AND DISTINGUISHING THEM FROM NORMAL HEMATOPIETIC STEM CELLS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: USES IN DIAGNOSIS, TREATMENT, AND RESEARCH
    Publication number: 20130079424
    Abstract: Using the methods of the present invention, intermediate (int) levels of aldehyde dehydrogenase (ALDH) activity reliably distinguished leukemic CD34+CD38? cells capable of engrafting immunodeficient mice, from residual normal hematopoietic stem cells that exhibited relatively higher ALDH activity. Minimal residual disease (MRD) detected during complete remission was enriched for the CD34+CD38?ALDHint leukemic cells, and the presence of these cells after therapy highly correlated with subsequent clinical relapse. The methods of the present invention can distinguish normal from leukemic CD34+CD38? cells, and identifies those AML cells associated with relapse. Methods of prediction of relapse of AML patients and methods of treatment are also provided.
    Type: Application
    Filed: September 24, 2012
    Publication date: March 28, 2013
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Jonathan Michael Gerber, Richard John Jones